MLC901 in hypoxic-ischemic brain injury patients: A double-blind, randomized placebo-controlled pilot study.

ABSTRACT:

Background

Hypoxic-ischemic brain injury (HIBI) is a disabling consequence of cardiopulmonary resuscitation, which has no direct treatment except supportive care. Many studies have used pharmacological agents to reduce or stop this disability. MLC901 is a traditional Chinese medicine showing neuroprotective and regenerative effects on focal and global ischemia in previous animal and human studies. We designed an experimental, randomized, double-blind, placebo-controlled study to analyze MLC901 efficacy in HIBI patients.

Methods

In a randomized, placebo-controlled trial, 35 patients with HIBI were randomly designated to receive either MLC901 or placebo capsules 3 times per day over 6 months. We assessed the 2 groups by modified Rankin Scale and Glasgow Outcome Scale at baseli

SUBMITTER: Pakdaman H 

PROVIDER: S-EPMC10256404 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature